The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19

[1]  Y. Hu,et al.  [Asymptomatic infection of COVID-19 and its challenge to epidemic prevention and control]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[2]  V. Fuster,et al.  Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[3]  Thomas J Oxley,et al.  Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young , 2020, The New England journal of medicine.

[4]  C. Roy,et al.  Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels , 2020, Radiology.

[5]  P. Calame,et al.  Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography , 2020, Radiology.

[6]  Nathaniel Hupert,et al.  Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.

[7]  Yutao Guo,et al.  COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up , 2020, Journal of the American College of Cardiology.

[8]  W. Liang,et al.  Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19 , 2020, The Lancet Haematology.

[9]  Xiaowei Yan,et al.  Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 , 2020, The New England journal of medicine.

[10]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[11]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[12]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[13]  R. Agha,et al.  World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19) , 2020, International Journal of Surgery.

[14]  Hongzhou Lu,et al.  Clinical observation and management of COVID-19 patients , 2020, Emerging microbes & infections.

[15]  J. Pittet,et al.  The coagulopathy of acute sepsis , 2015, Current opinion in anaesthesiology.

[16]  E. V. van Gorp,et al.  Review: Viral infections and mechanisms of thrombosis and bleeding† , 2012, Journal of medical virology.

[17]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[18]  Chengyu Jiang,et al.  Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans , 2011, PloS one.

[19]  B. Dixon,et al.  Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury , 2010, Critical care.

[20]  B. Dixon,et al.  Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial , 2010, Critical care.

[21]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[22]  A. Lazzarin,et al.  Coronaviridae and SARS-associated Coronavirus Strain HSR1 , 2004, Emerging infectious diseases.

[23]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[24]  D. Herndon,et al.  Heparin Nebulization Attenuates Acute Lung Injury in Sepsis Following Smoke Inhalation in Sheep , 2002, Shock.

[25]  A. Artigas,et al.  Anticoagulant therapy in acute respiratory distress syndrome. , 2018, Annals of translational medicine.

[26]  D. Xavier,et al.  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[27]  C. Keenan,et al.  Effects of race and ethnicity on the incidence of venous thromboembolism. , 2009, Thrombosis research.